KNBIF — Stock Film
STOCK FILMSCENE 1/10KNBIF · $0.03
Stock Expert AI presents
KNBIF
Kane Biotech Inc
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Kane Biotech Inc. A quick introduction.

On the stock market since 2007, it operates in the world of health and science. It has 20 employees. Now — the numbers.

on the stock market since 2007
20 employees
$5.1M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $7.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 28% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$1.6M
2021
$2.7M
2022
$149K
2023
$2.1M
2024
$428K
2025
In the vault right now:
$0
DEBT: $2.3M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Each sale is made at a loss3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

THE BRIGHT SIDE

Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $2.7M against $428K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.03. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, KNBIF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: KNBIF is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film